Modulation of Therapeutic Response
Modulation of Therapeutic Response
批准号:
7594757
负责人:
JAMES B MITCHELL
金额:
$63.51万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
Adverse effectsAnimalsAttentionBindingCell CycleCell HypoxiaCellsChemicalsClinical TrialsDNA DamageDNA RepairDataDoseElectron Spin Resonance SpectroscopyEvaluationFibroblastsFibrosisFutureGenesGoalsHalofuginoneHumanHypoxiaImageIn VitroInvasiveIonizing radiationKnockout MiceLate EffectsLoratadineMitosisModificationMolecularMolecular ProfilingMolecular TargetMusNormal tissue morphologyOxygenPathway interactionsPatientsPhysiologyPositron-Emission TomographyProcessRadiationRadiation Induced DNA DamageRadiation-Induced Gene ExpressionRadiation-Protective AgentsRadioactiveRadiobiologyResearchResearch DesignResistanceSignal TransductionSolid NeoplasmTGF Beta Signaling PathwayTherapeuticTracerTransforming Growth Factor betaTranslatingTumor-Associated Processcancer therapychemotherapycopper (II) diacetyl-di(N(4)-methylthiosemicarbazone)gene inductionimprovedin vivoinhibitor/antagonistinstrumentationinterestkinase inhibitorneoplastic cellnovelpre-clinical researchpreclinical studypregna-4,17-diene-3,16-dioneradiation effectreceptorresponsesoft tissuetrendtumoruptake
中文摘要
治疗反应的调节为了改善癌症治疗,辐射损伤的调节已经引起了相当大的关注。各种化疗和/或分子靶向药物与辐射的相互作用正在研究中,以确定是否可以使肿瘤更敏感,或使正常组织对放射治疗更具抵抗力。中心目标是确定将导致净治疗收益的方法,从而改善癌症的放射治疗。该项目的目标之一是定义和更好地了解肿瘤生理学的这些方面,包括细胞和分子过程以及肿瘤微环境对治疗反应的影响。已经完成的两项独立研究表明,在体外暴露的细胞与在体内作为实体肿瘤生长的相同细胞,辐射诱导的基因表达谱显着不同,进一步强调了肿瘤微环境对辐射反应的影响。此外,我们还表明,与单剂量放射治疗相比,多部分放射治疗能更有效地诱导基因表达。关于肿瘤的微环境,人们早就知道肿瘤细胞缺氧会导致对放化疗的抵抗。非侵入性成像可以识别肿瘤是缺氧的患者,这将在临床上有用。用动态正电子发射断层扫描(PET)技术对一种可能的放射性低氧标志物[64Cu]Cu-ATSM在荷瘤小鼠体内进行了评价。虽然这种PET示踪剂热切地结合到肿瘤上,但当肿瘤的氧合水平被调节时,它无法预测到不同数量的缺氧的变化。相反,随着肿瘤中氧气水平的降低,[18F]氟异硝唑显示出积极的趋势,肿瘤摄取更多。未来非侵入性评估肿瘤缺氧的尝试将使用电子顺磁共振成像(辐射生物学分部开发的仪器)与氧敏感化学探测器相结合进行评估。增强肿瘤对辐射的反应,而不增强给定治疗范围内的正常组织的能力是可取的。我们最近发现氯雷他定和古格列酮在体外可以增强肿瘤细胞的辐射反应。初步的机制研究表明,氯雷他定在细胞周期中施加G2/M期阻滞(细胞周期的G2/M期对辐射非常敏感)和桂皮酮,这似乎干扰了辐射诱导的DNA损伤修复。目前正在对这两种药物与放射联合应用于荷瘤小鼠的评估中。关于正常组织对辐射的反应,众所周知,转化生长因子β信号通路是辐射诱导的晚期效应(纤维化)的主要参与者。我们以前的研究表明,缺乏转化生长因子β信号的小鼠(Smad3基因敲除小鼠-转化生长因子β途径的下游信号中间产物)在接受高剂量辐射治疗时对纤维化具有抵抗力。我们最近发现,从这些动物中分离出来的成纤维细胞(与野生型成纤维细胞相比)在暴露于辐射时会增强其DNA损伤感知机制,并减少促纤维化基因的诱导。这些基础研究表明,以转化生长因子β途径为靶点的分子靶向药物可能对辐射诱导的纤维化提供显著的保护,这是放射治疗的一种不良副作用。最近的小鼠正常组织研究表明,使用在多个点针对转化生长因子β途径的常青藤酮或转化生长因子β1型受体激酶抑制剂,可显著减少辐射诱导的软组织纤维化。目前的研究集中在确认这两种药物在体内影响其分子靶点。这些临床前研究的目标是获得足够的疗效数据,将这些药物引入人类临床试验。
英文摘要
Modulation of Therapeutic Response Summary In the interest of improving cancer treatment, considerable attention has been placed on the modification of radiation damage. The interaction of a variety of chemotherapy and/or molecularly targeted agents with radiation is under study to determine if tumors can be made more sensitive or normal tissues more resistant to radiation treatment. The central aim is to identify approaches that will result in a net therapeutic gain, thus improving cancer treatment with radiation. One goal of the project is to define and better understand those aspects of tumor physiology, including cellular and molecular processes and the influence of the tumor microenvironment on treatment response. Two independent studies have been completed showing that radiation-induced gene expression profiles differ significantly for cells exposed in vitro versus the same cells growing as a solid tumor in vivo further underscoring the influence of the tumor microenvironment on the radiation response. Further we have shown that multi-fraction radiation delivery results in a more robust induction of genes than single dose radiation treatment. With respect to the tumor microenvironment, it has long been known that tumor cell hypoxia can cause resistance to radiation and chemotherapy treatment. Non-invasive imaging that could identify patients whose tumors are hypoxic would be useful clinically. A putative radioactive hypoxia marker, [64Cu]Cu-ATSM, was evaluated in tumor-bearing mice using dynamic positron emission tomography (PET). While this PET tracer avidly bound to tumor, it was unable to predictably detect changes in varying amounts of hypoxia when oxygenation levels of the tumor were modulated. In contrast, [18F]fluoromisonidazole demonstrated a positive trend with more tumor uptake as oxygen levels were lowered in the tumor. Future attempts of non-invasively assessing tumor hypoxia will be evaluated using electron paramagnetic resonance imaging (instrumentation developed in the Radiation Biology Branch) in conjunction with oxygen sensitive chemical probes. The ability to enhance the response of the tumor to radiation, without enhancing normal tissue within a given treatment field is desirable. We have recently shown that loratadine and guggulsterone enhance tumor cell radiation response in vitro. Preliminary mechanistic studies indicate that loratadine imposes a G2/M block in cell cycle (G2/M phases of the cell cycle are very radiosensitive) and guggulsterone, which appears to interfere with radiation-induced DNA damage repair. Evaluation of both agents in combination with radiation in tumor bearing mice is currently underway. With respect to normal tissue response to radiation, it is widely known that the TGF beta signaling pathway is a major player in radiation-induced late effects (fibrosis). Our previous studies have shown that mice deficient in TGF beta signaling (Smad3 knock-out mice-downstream signaling intermediate in the TGF beta pathway) are resistant to fibrosis when treated with high dose radiation. We have recently shown that fibroblasts isolated from these animals (compared to wild type fibroblasts) when exposed to radiation increase their DNA damage sensing mechanisms and decrease induction of pro-fibrotic genes. These basic studies suggest that targeting the TGF beta pathway with molecularly targeted agents may provide significant protection against radiation-induced fibrosis, an untoward side effect of radiation treatment. Recent mouse normal tissue studies using halofuginone, which targets the TGF beta pathways at several points or a TGF beta type 1 receptor kinase inhibitor have shown marked reduction in radiation-induced soft tissue fibrosis. Current studies are centered in confirming that both agents impact their molecular targets in vivo. The goal of these pre-clinical studies is to gain enough efficacy data to introduce these agents into human clinical trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Modulation of Therapeutic Response
-
批准号:6947107
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
Radiolysis, Photolysis, Sonolysis and Sonoprotection of
-
批准号:7331390
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
Nitroxides as Protectors Against Oxidative Stress
-
批准号:7594762
-
项目类别:
-
资助金额:$63.51万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
NITROXIDES AS PROTECTORS AGAINST OXIDATIVE STRESS
-
批准号:6290749
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
Nitroxides as Protectors Against Oxidative Stress
-
批准号:7292012
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
Modulation of Therapeutic Response
-
批准号:7292006
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
Modulation of Therapeutic Response
-
批准号:7331383
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
Modulation of Therapeutic Response
-
批准号:7735357
-
项目类别:
-
资助金额:$44.88万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
Modulation of Therapeutic Response
-
批准号:7066825
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
Modulation of Therapeutic Response
-
批准号:6756256
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
Modulation of Therapeutic Response
-
批准号:6433342
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
Modulation of Therapeutic Response
-
批准号:6558297
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
Nitroxides as Protectors Against Oxidative Stress
-
批准号:6558332
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
Nitroxides as Protectors Against Oxidative Stress
-
批准号:6756263
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
Nitroxides as Protectors Against Oxidative Stress
-
批准号:7735362
-
项目类别:
-
资助金额:$44.88万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
Nitroxides as Protectors Against Oxidative Stress
-
批准号:6433348
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
MODULATION OF THERAPEUTIC RESPONSE
-
批准号:6290743
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:JAMES B MITCHELL
-
依托单位:
海外基金